Meridian bioscience stock.

Meridian Bioscience Inc. (VIVO) Company Bio. Meridian Biosciences is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. The company was founded in 1976 and is ...A South Korean buyer consortium is acquiring US diagnostic test kit maker Meridian Bioscience (NASDAQ:VIVO). The offer is $34 per share in cash or a total of ~$1.53bn. The offer is $34 per share ...Jan 31, 2023 · The estimated Net Worth of John P. Kenny is at least 17.5 百万$ dollars as of 24 June 2022. Mr Kenny owns over 74,996 units of Meridian Bioscience stock worth over 11,093,515$ and over the last 5 years he sold VIVO stock worth over 4,939,280$. In addition, he makes 1,508,705$ as Pres、 CEO & Director at Meridian Bioscience.Dec 12, 2022 · Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced that it has entered into a side letter with the buyer ... Meridian Bioscience Inc. Common Stock (VIVO) Advanced Charting - Nasdaq offers advanced charting & market activity data for US and global markets.

Jan 14, 2022 · Phillips owns over 7,500 units of Meridian Bioscience stock worth over $477,109 and over the last 20 years he sold VIVO stock worth over $0. In addition, he makes $148,167 as Independent Chairman of the Board at Meridian Bioscience. Wallmine is a radically better financial terminal. Sign up in seconds, it's free!

Oct 10, 2017 · l28988ae10vk.htm MERIDIAN BIOSCIENCE, INC. 10-K. MERIDEIAN BIOSCIENCE, INC. 10-K. Washington, D.C. 20549. FOR ANNUAL AND TRANSITION REPORTS PURSUANT TO SECTIONS 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934. FOR THE FISCAL YEAR ENDED SEPTEMBER 30, 2007.

Oct 10, 2017 · l28988ae10vk.htm MERIDIAN BIOSCIENCE, INC. 10-K. MERIDEIAN BIOSCIENCE, INC. 10-K. Washington, D.C. 20549. FOR ANNUAL AND TRANSITION REPORTS PURSUANT TO SECTIONS 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934. FOR THE FISCAL YEAR ENDED SEPTEMBER 30, 2007.Marco Calzavara VIVO stock SEC Form 4 insiders trading. Marco has made over 1 trades of the Meridian Bioscience stock since 2013, according to the Form 4 filled with the SEC. Most recently Marco sold 3,200 units of VIVO stock worth $69,792 on 30 May 2013.. The largest trade Marco's ever made was selling 3,200 units of Meridian …Meridian Bioscience Inc is an integrated life science company. It develops and distributes diagnostic tests and reagents, as well as biologic substances used by pharmaceutical and biotechnology companies. Its Diagnostics segment manufactures tests primarily for gastrointestinal, viral, respiratory, & parasitic infectious diseases.7 juil. 2022 ... Meridian Biosciences (VIVO) Stock Trending on $1.5 Billion Buyout Agreement · Meridian Bioscience (VIVO) agreed to be acquired by SD Biosensor ...

37.23M. MSFT. 378.61. +0.31%. 20.54M. View today's Meridian Bioscience Inc stock price and latest VIVO news and analysis. Create real-time notifications to follow any changes in the live stock price.

Meridian’s stock soared 79% during that fiscal year. Newtown-based Meridian, founded in 1977, is Greater Cincinnati’s 16th-largest public company, according to Courier research. It reported ...

Meridian Bioscience, Inc. is a life science company. The Company is engaged in the development, manufacture, sale and distribution of diagnostic testing systems and kits, primarily for certain gastrointestinal and respiratory infectious diseases, and elevated blood lead levels; and the manufacture and distribution of bulk antigens, antibodies, immunoassay blocking reagents, specialized ... Insiders trading at Meridian Bioscience. Over the last 21 years, insiders at Meridian Bioscience have traded over $8,089,514 worth of Meridian Bioscience stock and bought 228,244 units worth $3,053,655 . The most active insiders traders include Richard Eberly, John P. Kenny, and John A Kraeutler.On average, Meridian Bioscience …VIVO stock is in the headlines as the company discloses a financial update. Meridian Bioscience ( VIVO) agreed to be acquired by SD Biosensor and SJL Partners in a $1.53 billion deal. Also, the ...Meridian Bioscience ( NASDAQ: VIVO) is a fast-growing company in the medical device industry. It has demonstrated a strong profitability record of approximately 60% gross profit margin and 20% ...Jan 31, 2023 · The estimated Net Worth of Anthony P Iii Bihl is at least $2.24 Million dollars as of 17 May 2022. Mr. Bihl owns over 20,000 units of Meridian Bioscience stock worth over $2,242,020 and over the last 7 years he sold VIVO stock worth over $0. In addition, he makes $0 as Independent Director at Meridian Bioscience.

As a publicly traded company, ownership of Meridian Bioscience, Inc. is constantly changing as shares are bought and sold on the stock market.Meridian Bioscience, Inc. (VIVO) Mission Statement The mission of Meridian Bioscience, Inc. is to provide diagnostic test kits, reagents, and related products and services that are of the highest quality ...Meridian Bioscience Corp - Company Profile and News - Bloomberg Markets Bloomberg Connecting decision makers to a dynamic network of information, people and ideas, …Meridian Bioscience Corp - Company Profile and News - Bloomberg Markets Bloomberg Connecting decision makers to a dynamic network of information, people and ideas, …CINCINNATI, Dec. 12, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO ), a leading global provider of diagnostic testing solutions and life science raw materials, announced that it has ...Jul 8, 2022 · Under the terms of the agreement, Meridian shareholders will receive $34.00 per share in cash, which represents a premium of approximately 32% over Meridian's closing stock price on the day before ...

Oct 10, 2017 · l28988ae10vk.htm MERIDIAN BIOSCIENCE, INC. 10-K. MERIDEIAN BIOSCIENCE, INC. 10-K. Washington, D.C. 20549. FOR ANNUAL AND TRANSITION REPORTS PURSUANT TO SECTIONS 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934. FOR THE FISCAL YEAR ENDED SEPTEMBER 30, 2007.Follow. CINCINNATI and MODIIN, Israel, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) and Exalenz Bioscience Ltd. (TASE: EXEN) announced today that the two companies ...

Discover historical prices for SLM stock on Yahoo Finance. View daily, weekly or monthly format back to when SLM Corporation stock was issued.Jan 31, 2023 · Meridian Bioscience, Inc. is a life science company. The Company is engaged in the development, manufacture, sale and distribution of diagnostic testing systems and kits, primarily for certain gastrointestinal and respiratory infectious diseases, and elevated blood lead levels; and the manufacture and distribution of bulk antigens, antibodies, immunoassay blocking reagents, specialized ... Mr. Phillips VIVO stock SEC Form 4 insiders trading. David has made over 8 trades of the Meridian Bioscience stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 7,500 units of VIVO stock worth $139,050 on 12 January 2022.. The largest trade he's ever made was buying 10,000 units of Meridian …Dec 13, 2022 · A high-level overview of Meridian Bioscience, Inc. (VIVO) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Halfway between the prime meridian and the 180-degree longitude line is a 90-degree longitude line. There are two 90-degree meridians (lines of longitude), one in each hemisphere. All of the lines of longitude to the west of the prime merid...Jan 31, 2023 · About Meridian Bioscience, Inc. Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products. The estimated Net Worth of James M. Anderson is at least $1.07 Million dollars as of 6 January 2023. Mr. Anderson owns over 8,500 units of Meridian Bioscience stock worth over $958,769 and over the last 14 years he sold VIVO stock worth over $0. In addition, he makes $114,667 as Independent Director at Meridian Bioscience.The estimated Net Worth of James M. Anderson is at least $1.07 Million dollars as of 6 January 2023. Mr. Anderson owns over 8,500 units of Meridian Bioscience stock worth over $958,769 and over the last 14 years he sold VIVO stock worth over $0. In addition, he makes $114,667 as Independent Director at Meridian Bioscience.Meridian Bioscience, Inc. is a life science company. The Company is engaged in the development, manufacture, sale and distribution of diagnostic testing systems and kits, primarily for certain gastrointestinal and respiratory infectious diseases, and elevated blood lead levels; and the manufacture and distribution of bulk antigens, antibodies, immunoassay blocking reagents, specialized ...The opportunity to support authentic relationships is what motivates our teams to create accurate solutions that span the range from discovery to diagnosis. We work hard every day to build genuine connections with all of our customers because even in the complex world of healthcare, the solution is simple. We’re here to help people, and we ...

Dec 12, 2022 · Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced that it has entered into a side letter with the buyer ...

Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 33.33% and 2.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues …

Find the latest Meridian Bioscience, Inc. (VIVO) stock quote, history, news and other vital information to help you with your stock trading and investing.Find Salaries by Job Title at Meridian Bioscience. 31 Salaries (for 13 job titles) • Updated Oct 29, 2023. How much do Meridian Bioscience employees make? Glassdoor provides our best prediction for total pay in today's job market, along with other types of pay like cash bonuses, stock bonuses, profit sharing, sales commissions, and tips.Meridian Bioscience (NASDAQ:VIVO) is a fully-integrated developer of diagnostic systems through its diagnostics segment, ... That means Meridian is a highly valued stock right now, ...19 fév. 2020 ... pylori detection and is currently evaluating additional applications of the BreathID platform. Exalenz's shares are traded on the Tel Aviv Stock ...The estimated total pay for a Account Executive at Meridian Bioscience is $167,272 per year. ... Additional pay could include bonus, stock, commission, profit sharing or tips. The "Most Likely Range" represents values that exist within the 25th and 75th percentile of all pay data available for this role.Marco Calzavara VIVO stock SEC Form 4 insiders trading. Marco has made over 1 trades of the Meridian Bioscience stock since 2013, according to the Form 4 filled with the SEC. Most recently Marco sold 3,200 units of VIVO stock worth $69,792 on 30 May 2013.. The largest trade Marco's ever made was selling 3,200 units of Meridian …Looking at the universe of stocks we cover at Dividend Channel, on 8/1/13, Meridian Bioscience Inc. (NASD: VIVO) will trade ex-dividend, for its quarterly dividend of $0.19, payable on 8/15/13. TipRanks | Stock Market Research, News and Analyst Forecasts - TipRanks.comThe stock of Meridian Bioscience (NAS:VIVO, 30-year Financials) shows every sign of being fairly valued, according to GuruFocus Value calculation.Meridian Bioscience, Inc. is a life science company. The Company is engaged in the development, manufacture, sale and distribution of diagnostic testing systems and kits, primarily for certain gastrointestinal and respiratory infectious diseases, and elevated blood lead levels; and the manufacture and distribution of bulk antigens, antibodies, immunoassay blocking reagents, specialized ...Curian is a rapid diagnostic solution for immunoassay detection of gastrointestinal diseases. It quickly and accurately identifies H. pylori, Campylobacter, and Shiga Toxin E. coli active infections. New tests are continuously being added to improve gastrointestinal outcomes and build a healthier community. The opportunity to support authentic relationships is what motivates our teams to create accurate solutions that span the range from discovery to diagnosis. We work hard every day to build genuine connections with all of our customers because even in the complex world of healthcare, the solution is simple. We’re here to help people, and we ...

Meridian Bioscience (NASDAQ:VIVO) is a fully-integrated developer of diagnostic systems through its diagnostics segment, ... That means Meridian is a highly valued stock right now, and the prices ...Curian is a rapid diagnostic solution for immunoassay detection of gastrointestinal diseases. It quickly and accurately identifies H. pylori, Campylobacter, and Shiga Toxin E. coli active infections. New tests are continuously being added to improve gastrointestinal outcomes and build a healthier community. As a publicly traded company, ownership of Meridian Bioscience, Inc. is constantly changing as shares are bought and sold on the stock market.Meridian Bioscience, Inc. (VIVO) Mission Statement The mission of Meridian Bioscience, Inc. is to provide diagnostic test kits, reagents, and related products and services that are of the highest quality ...Instagram:https://instagram. vision plans for seniorsmrvl share pricenow nasdaqlincoln national corp Meridian is an Ohio corporation and, therefore, governed by the corporate laws of Ohio. Since its stock is publicly traded on Nasdaq and it files reports with the Securities and Exchange Commission, it is also subject to NASD rules as well as various provisions of federal securities laws as recently changed by the Sarbanes-Oxley Act. Dec 12, 2022 · Meridian Bioscience, Inc. is a life science company. The Company is engaged in the development, manufacture, sale and distribution of diagnostic testing systems and kits, primarily for certain gastrointestinal and respiratory infectious diseases, and elevated blood lead levels; and the manufacture and distribution of bulk antigens, antibodies, immunoassay blocking reagents, specialized ... polestar salesberkshire hathaway dividends Meridian Bioscience ( NASDAQ: VIVO) is a fast-growing company in the medical device industry. It has demonstrated a strong profitability record of approximately 60% gross profit margin and 20% ... group on news Meridian Bioscience hits 52-week high; stock up 36% YTD SA News Wed, Jun. 08, 2022 2 Comments. Meridian Biosciences says its qPCR mixes can be used in monkeypox molecular testsJul 7, 2022 · SD Biosensor Inc (SDB) and SJL Partners LLC have agreed to acquire Meridian Bioscience Inc (NASDAQ:VIVO) in an all-cash transaction valued at approximately $1.53 billion.; Under the terms of the ...